Teva to Acquire Allergan Generics, Withdraws from Mylan Deal


July 27, 2015.

Teva Pharmaceutical Industries Ltd. (Petach Tikva, Israel) has announced that it has signed a definitive agreement to acquire the generics business of Allergan (Dublin, Ireland) in a transaction valued at $40.5 billion.   Upon closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion.     The Israeli firm simultaneously announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (Amsterdam, The Netherlands).

Related Videos
Related Content